EXPORT CITATION

Chapter-092 Type 1 Diabetes (Pediatric Endocrinology)

BOOK TITLE: ESI Manual of Clinical Endocrinology

Author
1. Chowdhury Subhankar
2. Shrivastav Ankit
ISBN
9789351526476
DOI
10.5005/jp/books/12535_116
Edition
2/e
Publishing Year
2015
Pages
8
Author Affiliations
1. Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, IPGME & R and SSKM Hospital, Kolkata, West Bengal, India, IPGME and R, Kolkata, West Bengal, India, Institute of Post Graduate Medical Education & Research and SSKM Hospital, Kolkata, West Bengal, India, Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India, IPGMER and SSKM Hospital, Kolkata, West Bengal, India
2. Medical superspeciality Hospital, Ranchi, Jharkhand, India
Chapter keywords
Type 1 diabetes mellitus, insulinopenia, insulinoma-associated protein 2, medical nutrition therapy, humanized monoclonal antibody

Abstract

Type 1 diabetes mellitus (T1DM) is a chronic metabolic disorder characterized by pancreatic islet β-cell destruction and absolute insulinopenia. T1DM is classified into type 1A and type 1B. The clinical symptoms of T1DM are secondary to hyperglycemia, glycosuria and DKA. The management of a child with T1DM may be divided into initial care at presentation, establishing metabolic control and an ongoing age-based guidance system. The aim of dietary management is to balance the child’s food intake with insulin dose and to keep blood glucose concentrations as close as possible to reference ranges. The most physiological approach to insulin involves CSII via an insulin pump. Education is a continuing process involving the child, family, and all members of the diabetes team. T1DM is dependent upon the age of the patient, which impacts the risk of hypoglycemia and development of self-management skills. Hypoglycemia is a constant concern because of the erratic food intake and activity levels of toddlers. Phase I/II clinical trials use monoclonal antibodies against CD3, hOKT31 and ChAglyCD3 shows reduction in insulin production in patients with newly diagnosed with T1DM.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved

Powered by MPS ScholarStor